Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-30

Study Completion Date

2019-11-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ocular toxoplasmosis (OT) is a major cause of visual impairment worldwide. OT is responsible for 30 to 50% of posterior uveitis. It is characterized by dormant infections that may reactivate without known reasons, causing severe irreversible visual loss. The overall recurrence rate of OT in Europe is greater than 80% for patients and may range from one episode to 11 episodes (1% of OT) in the most extreme cases. Current treatments do not reduce the risk of recurrences and the risk of toxoplasmosis recurrence cannot be predicted in these immunocompetent patients. These clinical and biological expression changes might be related to an individual genetic susceptibility of each patient. The advanced analysis of the entire genome now possible to consider the project.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis

NCT02556866

Cryoglobulinemia Systemic Vasculitis

TERMINATED PHASE2

Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL)

NCT00974883

Giant Cell Arteritis

COMPLETED

Genetic Susceptibility Factors for Candidemia.

NCT02841501

Invasive Candidiasis Candidemia Genetic Predisposition to Disease

COMPLETED

Genetics and Epigenetics of Graves' Orbitopathy

NCT04488406

Graves Ophthalmopathy

COMPLETED

Microbiological Diagnosis of Infectious Uveitis to Pathogenic Fastidious Germs

NCT02819206

Uveitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Toxoplasmosis Infection Genotype II Ocular Toxoplasmosis With Recurrences

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

seropositive for Toxoplasma gondii

Group Type EXPERIMENTAL

seropositive for Toxoplasma gondii

Intervention Type BIOLOGICAL

blood sample

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

seropositive for Toxoplasma gondii

blood sample

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* seropositive for Toxoplasma gondii (for patient and parents)
* Infection with genotype II (for patient and parents)
* ocular toxoplasmosis recurrences \>5 (patients only)